anti-Mycn (MYCN) Antibodies

MYCN is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. Additionally we are shipping MYCN Kits (8) and MYCN Proteins (7) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
MYCN 4613 P04198
MYCN 18109 P03966
MYCN 298894 Q63379
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-MYCN Antibodies at

Showing 10 out of 99 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Rabbit Un-conjugated IF (p), IHC (p), WB 100 μL Log in to see 3 to 7 Days
Human Rabbit Un-conjugated WB 100 μg Log in to see 4 to 6 Days
Cow Rabbit Un-conjugated WB WB Suggested Anti-MYCN Antibody Titration:  2.5ug/ml  Positive Control:  Human heart 100 μL Log in to see 2 to 3 Days
Human Mouse Un-conjugated ChIP, CyTOF, FACS, GS, ICC, IF, IP, WB Immunocytochemistry/ Immunofluorescence: n-Myc Antibody (NMYC-1) [ABIN152254] - The n-Myc (NMYC-1) antibody was tested in NTERA2 cells at a 1:50 dilution against Dylight 488 (Green). Actin and nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively. Western Blot: n-Myc Antibody (NMYC-1) [ABIN152254] - Western blot analysis of n-Myc expression in human heart tissue. 0.1 mL Log in to see 7 to 9 Days
Human Rabbit Un-conjugated WB Western blot analysis of MYCN antibody (C-term) (ABIN391590) in CEM cell line lysates (35 µg/lane). MYCN (arrow) was detected using the purified polyclonal antibody. Anti-MYCN Antibody (C-term) at 1:1000 dilution + CCRF-CEM whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 50 kDa Blocking/Dilution buffer: 5% NFDM/TBST. Dilution: 1:1000 400 μL Log in to see 10 to 11 Days
Human Mouse Un-conjugated ELISA, WB Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (36.74 KDa) . Dilution: 1:500~1000 100 μg Log in to see 8 to 11 Days
Bat Rabbit Un-conjugated WB 100 μg Log in to see 11 to 14 Days
Human Rabbit Un-conjugated EIA, WB Western blot analysis of MYCN antibody (C-term) in CEM cell line lysates (35ug/lane). MYCN (arrow) was detected using the purified Pab. 0.4 mL Log in to see 6 to 8 Days
Human Rabbit Un-conjugated ELISA, IHC, WB ABIN6268752 at 1/100 staining human brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. Western blot analysis of N Myc expression in CACO-2 cells 100 μL Log in to see 11 to 12 Days
Human Rabbit Un-conjugated WB Immunohistochemistry of paraffin-embedded mouse brain using MYCN antibody. 100 μL Log in to see 16 Days

Top referenced anti-MYCN Antibodies

  1. Human Monoclonal MYCN Primary Antibody for ChIP, CyTOF - ABIN152254 : Tasseva, Cole, Vance: N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells. in The Journal of biological chemistry 2011 (PubMed)
    Show all 3 Pubmed References

  2. Mouse (Murine) Polyclonal MYCN Primary Antibody for ICC, IF - ABIN256650 : Sjostrom, Finn, Hahn, Rowitch, Kenney: The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. in Developmental cell 2005 (PubMed)
    Show all 2 Pubmed References

  3. Human Polyclonal MYCN Primary Antibody for IF (p), IHC (p) - ABIN760676 : Ramraj, Aravindan, Somasundaram, Herman, Natarajan, Aravindan: Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. in Oncotarget 2016 (PubMed)

  4. Human Polyclonal MYCN Primary Antibody for WB - ABIN391590 : Li, Sun, Chen, Squires, Nowroozizadeh, Liang, Huang: p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. in Molecular cancer research : MCR 2015 (PubMed)

  5. Human Polyclonal MYCN Primary Antibody for WB - ABIN6669579 : Chang, Yang, Zheng, Li, Nie: Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer. in American journal of translational research 2016 (PubMed)

More Antibodies against MYCN Interaction Partners

Human Mycn (MYCN) interaction partners

  1. TFAP4 is a key regulator of MYCN-amplified neuroblastom

  2. restoration of MYCN reversed the effects of miR5013p in cisplatinresistant glioma cells. In conclusion, these results suggested that miR5013p may serve a promising marker for cisplatin resistance.

  3. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

  4. This suggested that NMyc regulated survival and growth of CHP134 and BE2C neuroblastoma cells, potentially through Wnt/betacatenin signaling. Furthermore, associated proteins, NMyc and STAT interactor and dickkopf Wnt signaling pathway inhibitor 1, were demonstrated to be involved in this regulation.

  5. In this report, we present a case with Feingold Syndrome having a novel mutation in MYCN gene and discuss genetic counselling and prenatal diagnosis due to pregnancy of the patient's mother.

  6. Results demonstrated that MYCN expression was downregulated in cholangiocarcinoma (CCA) through a mechanism involving miR-5095 binding its 3'UTR.

  7. MYCN levels are regulated transcriptionally by MYCNOS-01 (an alternative transcript of MYCNOS) in rhabdomyosarcoma and neuroblastoma cells.

  8. a MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma.

  9. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.

  10. Data indicate that inter-play between MYCN and the highly tumorigenic proteins which are upregulated in the malignant IMR-32 neuroblastoma cells may be fueling their aggressive behavior.

  11. these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR for liver cancer stem cell in de novo Hepatocellular carcinoma.

  12. Alternative nonhomologous DNA end-joining pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation have been revealed in the process of neuroblastoma initiation in mice.

  13. High TrkA expression is one of the most powerful predictor of good prognosis in neuroblastoma and is associated with younger age, lower stage, and absence of MYCN amplification

  14. The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma. Pharmacologic inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma.

  15. overexpression of MYCN promoted cell proliferation, and induced erythroid differentiation block and apoptosis resistance to cytotoxic agent. Knockdown of MYCN inhibited the expression of EZH2, and then activated p21 expression through removal of H3K27me3 at the p21 promoter.

  16. MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma.

  17. MYCN expression is regulated by ZAR1 in neuroblastoma.

  18. The target of miR-29b was predicted using miRanda, TargetScan and PicTar sofeware and authors also found MYCN was a direct target of miR-29b in glioma cells and miR-29b inhibited the proliferation of glioma cells via MYCN dependent way.

  19. eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a critical mediator of the adaptive response of MYCN amplified NB cells to metabolic stress.

  20. Among 30 samples of brain tumor, 14 cases revealed MYCN amplification. High-protein expression of MYCN was also observed in 43.3% of patients. There was a significant correlation between MYCN gene amplification and protein expression, interestingly five case showed discrepancy between the gene amplification and protein expression.

Mouse (Murine) Mycn (MYCN) interaction partners

  1. Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.

  2. MYCN-promoted SGO1 transcription and SGO1 expression tended to be higher in MYCN- or MYC-overexpressing cancers. Together, these findings indicate that SGO1 plays a role in the DNA damage response in interphase.

  3. interactions of NF-kappaB and N-myc with GLT-1/EAAT2 promoter sequences was significantly elevated in the ipsi-lateral cortex of both adult and old Traumatic brain injury mice.

  4. beta-catenin cooperates with the transcription factor Myc to activate the progenitor renewal program.

  5. we report the isolation and propagation of neuroblastoma sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma with MYCN amplification

  6. miR-34a contributes to the expansion of Myeloid-derived suppressor cells by inhibiting the apoptosis via suppressing the expression of N-myc.

  7. the role of N-myc in mouse lens development, was examined.

  8. Using comparative genomic hybridization, authors found that NCC-derived NBL tumors in mice acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL including 17q gain, 2p gain and loss of 1p36.

  9. a Mycn target gene encoding the miR cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.

  10. The findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers.

  11. ALKR1275Q cooperated with MYCN in the development of aggressive NB, possibly by downregulating the expression of ECM/BM-associated genes and by conferring malignant potentials to MYCN-expressing cells.

  12. Reuslts show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.

  13. Thus, this synergistic effect of ZD55-shMYCN in combination with doxorubicin provides a novel therapy strategy for doxorubicin-resistant neuroblastoma, and is a promising approach for further clinical development.

  14. demonstrate a critical link between Myc/Mycn gene activity and glycolysis in spermatogonial stem cell self-renewal

  15. Loss of N-myc significantly impairs the Sonic hedgehog signaling pathway and disrupts the expression of cell cycle effectors with a significant reduction of Ccnd2.

  16. Study shows that ground-state embryonic stem cells express low Myc levels. Deletion of both c-myc and N-myc activity strongly decreases transcription, splicing, and protein synthesis, leading to proliferation arrest; process is reversible and occurs without affecting pluripotency, suggesting that Myc-depleted stem cells enter a state of dormancy.

  17. MYCN overexpression is not sufficient for these cells to form tumors in nude mice

  18. ITGA4 expression enhances metastasis in MYCN low neuroblastoma.

  19. MYCN plays a critical role in expansion and survival of aggressive medulloblastoma-propagating cells.

  20. SUMOylation may be part of a quality-control mechanism acting on misfolded Myc proteins.

Zebrafish Mycn (MYCN) interaction partners

  1. In MYCN transgenic fish, Gab2 overexpression activated the Shp2-Ras-Erk pathway, enhanced neuroblastoma induction, and increased tumor penetrance.

  2. The authors demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos.

  3. At somitogenesis stages, nmyc1 expression was detected in the retina, midbrain, posterior hindbrain and presumptive spinal cord. It was also transcribed in the endoderm and its derivatives as well as in branchial arches.

MYCN Antigen Profile

Protein Summary

This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.

Gene names and symbols associated with anti-Mycn (MYCN) Antibodies

  • MYCN proto-oncogene, bHLH transcription factor (MYCN) antibody
  • v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) antibody
  • v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived (Mycn) antibody
  • MYCN proto-oncogene, bHLH transcription factor (Mycn) antibody
  • olfactory receptor 8S1 (LOC515887) antibody
  • MYCN proto-oncogene, bHLH transcription factor (mycn) antibody
  • MYCN proto-oncogene, bHLH transcription factor S homeolog (mycn.S) antibody
  • bHLHe37 antibody
  • c-nmyc antibody
  • fb57a02 antibody
  • MODED antibody
  • mycn antibody
  • mycn-a antibody
  • mycn-b antibody
  • mycna antibody
  • MYCNOT antibody
  • N-myc antibody
  • Nmuc1 antibody
  • Nmyc antibody
  • Nmyc-1 antibody
  • nmyc1 antibody
  • ODED antibody
  • wu:fb57a02 antibody
  • XN-myc antibody
  • xN-myc1 antibody
  • XNmyc antibody
  • zgc:85706 antibody

Protein level used designations for anti-Mycn (MYCN) Antibodies

N-myc proto-oncogene protein , class E basic helix-loop-helix protein 37 , neuroblastoma MYC oncogene , neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene , oncogene NMYC , pp65/67 , v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived , v-myc myelocytomatosis viral related oncogene, neuroblastoma derived , N-myc protein , neuroblastoma myc-related oncogene 1 , Avian myelocytomatosis viral (v-myc) related oncogene neuroblastoma derived (Nmyc) , Avian myelocytomatosis viral (v-myc) related oncogene, neuroblastoma derived (Nmyc) , N-myc-like protein , v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog , MYCN proto-oncogene, bHLH transcription factor S homeolog , v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog S homeolog , v-myc myelocytomatosis viral related oncogene, neuroblastoma derived, a

4613 Homo sapiens
482978 Canis lupus familiaris
421948 Gallus gallus
18109 Mus musculus
298894 Rattus norvegicus
515887 Bos taurus
252851 Danio rerio
380041 Xenopus laevis
Selected quality suppliers for anti-MYCN (MYCN) Antibodies
Did you look for something else?